| Name | Title | Contact Details |
|---|---|---|
David Demsey |
Head Of Information Security and Infrastructure | Profile |
Gemelli Biotech leverages leading biological discoveries related to the microbiome to provide non-invasive precision diagnostics which enable clinicians to definitively detect scientifically validated biomarkers and optimally treat GI diseases including SIBO, IMO, excess hydrogen sulfide and post-infectious IBS.
Lung Therapeutics pursues innovative treatments for underserved, life-threatening lung conditions.
Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.
At Ensoma, we believe every person, no matter where they are in the world, should have access to innovative technologies that are changing the way we treat disease.
The Broad Institute brings together a diverse group of individuals from across its partner institutions — undergraduate and graduate students, postdoctoral fellows, professional scientists, administrative professionals, and academic faculty. The culture and environment at the Broad is designed to encourage creativity and to engage all participants, regardless of role or seniority, in the mission of the Institute. Within this setting, researchers are empowered — both intellectually and technically — to confront even the most difficult biomedical challenges. The Institute`s organization is unique among biomedical research institutions. It encompasses three types of organizational units: core member laboratories, programs and platforms. Scientists within these units work closely together — and with other collaborators around the world — to tackle critical problems in human biology and disease.